MIF gene polymorphisms confer susceptibility to Vogt- Koyanagi-Harada syndrome in a Han Chinese population

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 12, 2013, Pages 7734-7738

  Zhang, Chunxia ^a   Liu, Shouli ^a   Hou, Shengping ^b   Lei, Bo ^b   Zheng, Xiuyun ^a   Xiao, Xiang ^b   Kijlstra, Aize ^c   Yang, Peizeng ^b  

^a Jinan Mingshui Eye Hospital   (China)

^b THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Disease association; Gene polymorphism; Macrophage migration inhibitory factor (MIF); Vogt Koyanagi Harada (VKH) syndrome

Indexed keywords

MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MACROPHAGE MIGRATION INHIBITION FACTOR GENE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; VOGT KOYANAGI SYNDROME;

DISEASE ASSOCIATION; GENE POLYMORPHISM; MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF); VOGT-KOYANAGI-HARADA (VKH) SYNDROME;

ADULT; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; DNA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; POLYMORPHISM, GENETIC; UVEOMENINGOENCEPHALITIC SYNDROME;

EID: 84888119791     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12187     Document Type: Article

References (36)

1. Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 1996;80:1002-1008.
2. Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000;165:7323-7329.
3. Islam SM, Numaga J, Matsuki K, Fujino Y, Maeda H, Masuda K. Influence of HLA-DRB1 gene variation on the clinical course of Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 1994;35:752-756.
4. Zetterquist H, Olerup O. Identification of the HLA-DRB1*04,-DRB1*07, and-DRB1*09 alleles by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Hum Immunol. 1992;34:64-74.
5. Hou S, Yang P, Du L, et al. Small ubiquitin-like modifier 4 (SUMO4) polymorphisms and Vogt-Koyanagi-Harada (VKH) syndrome in the Chinese Han population. Mol Vis. 2008;14:2597-2603.
6. Li K, Yang P, Zhao M, et al. Polymorphisms of FCRL3 in a Chinese population with Vogt-Koyanagi-Harada (VKH) syndrome. Mol Vis. 2009;15:955-961.
7. Shu Q, Yang P, Hou S, et al. Interleukin-17 gene polymorphism is associated with Vogt-Koyanagi-Harada syndrome but not with Behcet's disease in a Chinese Han population. Hum Immunol. 2010;71:988-991.
8. Hu K, Yang P, Jiang Z, Hou S, Du L, Li F. STAT4 polymorphism in a Chinese Han population with Vogt-Koyanagi-Harada syndrome and Behcet's disease. Hum Immunol. 2010;71:723-726.
9. Meng Q, Liu X, Yang P, et al. PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome. Mol Vis. 2009;15:386-392.
10. Baugh JA, Bucala R. Macrophage migration inhibitory factor. Crit Care Med. 2002;30:S27-S35.
11. Lolis E. Glucocorticoid counter regulation: macrophage migration inhibitory factor as a target for drug discovery. Curr Opin Pharmacol. 2001;1:662-668.
12. Donn R, Alourfi Z, Zeggini E, et al. A functional promoter haplotype of macrophage migration inhibitory factor is linked and associated with juvenile idiopathic arthritis. Arthritis Rheum. 2004;50:1604-1610.
13. Berdeli A, Ozyurek AR, Ulger Z, et al. Association of macrophage migration inhibitory factor gene-173 G/C polymorphism with prognosis in Turkish children with juvenile rheumatoid arthritis. Rheumatol Int. 2006;26:726-731.
14. Vivarelli M, D'Urbano LE, Insalaco A, et al. Macrophage migration inhibitory factor (MIF) and oligoarticular juvenile idiopathic arthritis (o-JIA): association of MIF promoter polymorphisms with response to intra-articular glucocorticoids. Clin Exp Rheumatol. 2007;25:775-781.
15. Akcali A, Pehlivan S, Pehlivan M, Sever T, Neyal M. Association of macrophage migration inhibitory factor gene promoter polymorphisms with multiple sclerosis in Turkish patients. J Int Med Res. 2010;38:69-77.
16. Sanchez E, Gomez LM, Lopez-Nevot MA, et al. Evidence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus. Genes Immun. 2006;7:433-436.
17. Donn RP, Plant D, Jury F, et al. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J Invest Dermatol. 2004;123:484-487.
18. Nohara H, Okayama N, Inoue N, et al. Association of the-173 G/C polymorphism of the macrophage migration inhibitory factor gene with ulcerative colitis. J Gastroenterol. 2004;39:242-246.
19. Kotake S, Kitaichi N, Ohno S. Macrophage migration inhibitory factor in uveitis. Int Ophthalmol Clin. 2002;42:99-103.
20. Kitaichi N, Kotake S, Sasamoto Y, et al. Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest Ophthalmol Vis Sci. 1999;40:247-250.
21. Kitaichi N, Kotake S, Mizue Y, et al. High-dose corticosteroid administration induces increase of serum macrophage migration inhibitory factor in patients with Vogt-Koyanagi-Harada's disease. Microbiol Immunol. 2000;44:1075-1077.
22. Zheng X, Wang D, Hou S, et al. Association of macrophage migration inhibitory factor gene polymorphisms with Behcet's disease in a Han Chinese population. Ophthalmology. 2012;119:2514-2518.
23. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131:647-652.
24. Fei BY, Lv HX, Yang JM, Ye ZY. Association of MIF-173 gene polymorphism with inflammatory bowel disease in Chinese Han population. Cytokine. 2008;41:44-47.
25. Wu SP, Leng L, Feng Z, et al. Macrophage migration inhibitory factor promoter polymorphisms and the clinical expression of scleroderma. Arthritis Rheum. 2006;54:3661-3669.
26. Shimizu T, Hizawa N, Honda A, et al. Promoter region polymorphism of macrophage migration inhibitory factor is strong risk factor for young onset of extensive alopecia areata. Genes Immun. 2005;6:285-289.
27. Barton A, Lamb R, Symmons D, et al. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun. 2003;4:487-491.
28. Donn R, Alourfi Z, De Benedetti F, et al. Mutation screening of the macrophage migration inhibitory factor gene: positive association of a functional polymorphism of macrophage migration inhibitory factor with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:2402-2409.
29. De Benedetti F, Meazza C, Vivarelli M, et al. Functional and prognostic relevance of the-173 polymorphism of the macrophage migration inhibitory factor gene in systemiconset juvenile idiopathic arthritis. Arthritis Rheum. 2003;48:1398-1407.
30. Assis DN, Leng L, Du X, et al. The role of macrophage migration inhibitory factor (MIF) in autoimmune liver disease [published online ahead of print August 2, 2013]. Hepatology. doi:10.1002/hep.26664.
31. Wang FF, Huang XF, Shen N, et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still's disease. Arthritis Res Ther. 2013;15:R65.
32. Zhong XB, Leng L, Beitin A, et al. Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies. Nucleic Acids Res. 2005;33: e121.
33. Greven D, Leng L, Bucala R. Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Targets. 2010;14:253-264.
34. Sreih A, Ezzeddine R, Leng L, et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum. 2011;63:3942-3951.
35. Bucala R, Lolis E. Macrophage migration inhibitory factor: a critical component of autoimmune inflammatory diseases. Drug News Perspect. 2005;18:417-426.
36. Andreoli CM, Foster CS. Vogt-Koyanagi-Harada disease. Int Ophthalmol Clin. 2006;46:111-122.